A Phase 2 interventional study of Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab) in Recurrent Small-cell Lung Cancer (SCLC) and Lung Cancer, Small Cell, sponsored by GlaxoSmithKline. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-27.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing topotecan in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, 2 of them phase 3. Topotecan · Small Cell Lung Carcinoma.
Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, this one is the 14th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2008, is one of 11 in phase 2, and was the 22nd registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →2 of the 29 studies testing topotecan in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Gilead Sciences · Sites in United States, Argentina, Australia and 20 more countries
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 7
First in 1995; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 44 across the 28 interventional studies. Of the 22 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 29 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
17 studies in Small Cell Lung Carcinoma by GlaxoSmithKline: 1 open now, 1 under way, 1 of them phase 3. Of 14 finished, 5 (36%) have results posted.
Among the 17 studies in Small Cell Lung Carcinoma by GlaxoSmithKline, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2008, is one of 5 in phase 2, and was the 8th registered.
GlaxoSmithKline’s Small Cell Lung Carcinoma studies by the year they started, since 2000.
2 of the studies testing topotecan in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06500026Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | 2026-12 |
| NCT06449209BioNTech SESafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 17 in Small Cell Lung Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung cancer and improve progression free survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral topotecan + IV Bevacizumab
Drug: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Drug page: Topotecan
2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
Percentage of Participants With Progression-free Survival (PFS) at 3 Months
PFS = time from initiation of drug to time of first disease progression/death due to any cause. Progression assessed using Response Evaluation Criteria (RECIST): \>=20% increase in sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion(s). If participant did not progress or die, the time of initiation of post-treatment anti-cancer therapy or time of last contact used. PFS at 3 months calculated by taking the Kaplan-Meier (KM) estimate at 90 days from the initiation of treatment. SE = standard error.
Time frame: 3 months
PFS - Overall
Progression-free survival at any site was defined as the time from initiation of investigational product to the time of first documented disease progression or death due to any cause. Progression was assessed using the RECIST guidelines: \>= 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion (s). For participants who did not progress or die, the time of initiation of post-treatment anti-cancer therapy or the time of last contact was used.
Time frame: Baseline to disease progression or death (up to 82.4 weeks)
Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)
Tumor response was determined using the RECIST guidelines.CR, disappearance of all target lesions; PR, \>=30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since treatment started; PD, \>=20% increase in sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Baseline to disease progression or death (up to 82.4 weeks)
Number of Participants With a Tumor Response (CR and PR)
Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD.
Time frame: Baseline to disease progression or death (up to 82.4 weeks)
Duration of Tumor Response (CR and PR)
Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. Duration of response is defined as the time from start of response (CR or PR) until progression or death due to any cause. For participants who did not progress or die, the time of initiation of post-treatment anti-cancer therapy or the time of last contact was used.
Time frame: Baseline to disease progression or death (up to 82.4 weeks)
Time to Tumor Response (CR and PR)
Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. Time to response is defined as the time from initiation of investigational product to the time of first documented response (CR or PR).
Time frame: Baseline to disease progression or death (up to 82.4 weeks)
Overall Survival
Overall survival is defined as the time from initiation of investigational product to death due to any cause. For participants who did not die, the time of last contact was used.
Time frame: Baseline to disease progression or death (up to 82.4 weeks)
| Milestone | Topotecan and Bevacizumab |
|---|---|
| Started | 50 |
| Completed | 45 |
| Not completed | 5 |
| Withdrew: Study termination | 2 |
| Withdrew: Withdrawal by subject | 3 |
PFS = time from initiation of drug to time of first disease progression/death due to any cause. Progression assessed using Response Evaluation Criteria (RECIST): \>=20% increase in sum of longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion(s). If participant did not progress or die, the time of initiation of post-treatment anti-cancer therapy or time of last contact used. PFS at 3 months calculated by taking the Kaplan-Meier (KM) estimate at 90 days from the initiation of treatment. SE = standard error.
| percentageof participants | Topotecan and Bevacizumab |
|---|---|
| Percentage of Participants With Progression-free Survival (PFS) at 3 Months | 65 |
Progression-free survival at any site was defined as the time from initiation of investigational product to the time of first documented disease progression or death due to any cause. Progression was assessed using the RECIST guidelines: \>= 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since treatment started, or appearance of new lesion (s). For participants who did not progress or die, the time of initiation of post-treatment anti-cancer therapy or the time of last contact was used.
| weeks | Topotecan and Bevacizumab: Resistant Participants | Topotecan and Bevacizumab: Sensitive Participants | Topotecan and Bevacizumab: All Participants |
|---|---|---|---|
| PFS - Overall | 12.64 (6.43 to 21.43) | 27.14 (16.14 to 32.57) | 17.43 (13.14 to 25.00) |
Tumor response was determined using the RECIST guidelines.CR, disappearance of all target lesions; PR, \>=30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since treatment started; PD, \>=20% increase in sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| participants | Topotecan and Bevacizumab: Resistant Participants | Topotecan and Bevacizumab: Sensitive Participants | Topotecan and Bevacizumab: All Participants |
|---|---|---|---|
| CR | 0 | 0 | 0 |
| PR | 2 | 6 | 8 |
| SD | 9 | 11 | 20 |
| PD | 9 | 4 | 13 |
| Unknown | 3 | 6 | 9 |
Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD.
| participants | Topotecan and Bevacizumab: Resistant Participants | Topotecan and Bevacizumab: Sensistive Participants | Topotecan and Bevacizumab: All Participants |
|---|---|---|---|
| Number of Participants With a Tumor Response (CR and PR) | 2 | 6 | 8 |
Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. Duration of response is defined as the time from start of response (CR or PR) until progression or death due to any cause. For participants who did not progress or die, the time of initiation of post-treatment anti-cancer therapy or the time of last contact was used.
| weeks | Topotecan and Bevacizumab |
|---|---|
| Duration of Tumor Response (CR and PR) | 20.6 (15.6 to 41.0) |
Tumor response was determined using the RECIST guidelines. CR: disappearance of all target lesions. PR: \>=30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. Time to response is defined as the time from initiation of investigational product to the time of first documented response (CR or PR).
| weeks | Topotecan and Bevacizumab |
|---|---|
| Time to Tumor Response (CR and PR) | 5.8 (5.3 to 12.7) |
Overall survival is defined as the time from initiation of investigational product to death due to any cause. For participants who did not die, the time of last contact was used.
| weeks | Topotecan and Bevacizumab: Resistant Participants | Topotecan and Bevacizumab: Sensitive Participants | Topotecan and Bevacizumab: All Participants |
|---|---|---|---|
| Overall Survival | 26.4 (18.1 to 38.0) | 37.0 (30.6 to 48.0) | 32.0 (26.4 to 39.3) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Topotecan and Bevacizumab | — | 18/50 (36%) | 50/50 (100%) |
| Event | Topotecan and Bevacizumab |
|---|---|
| PneumoniaInfections and infestations | 4/50 |
| DiarrhoeaGastrointestinal disorders | 3/50 |
| SepsisInfections and infestations | 2/50 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/50 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/50 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/50 |
| NauseaGastrointestinal disorders | 2/50 |
| VomitingGastrointestinal disorders | 2/50 |
| DehydrationMetabolism and nutrition disorders | 2/50 |
| Inappropriate antidiuretic hormone secretionEndocrine disorders | 2/50 |
| Event | Topotecan and Bevacizumab |
|---|---|
| FatigueGeneral disorders | 32/50 |
| NauseaGastrointestinal disorders | 30/50 |
| DiarrhoeaGastrointestinal disorders | 27/50 |
| AnaemiaBlood and lymphatic system disorders | 27/50 |
| Decreased appetiteMetabolism and nutrition disorders | 24/50 |
| NeutropeniaBlood and lymphatic system disorders | 22/50 |
| ThrombocytopeniaBlood and lymphatic system disorders | 21/50 |
| VomitingGastrointestinal disorders | 19/50 |
| ConstipationGastrointestinal disorders | 17/50 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/50 |
| Age Continuous(Years) | Topotecan and Bevacizumab |
|---|---|
| Mean | 60.8 ± 10.75 |
| Sex: Female, Male(Participants) | Topotecan and Bevacizumab |
|---|---|
| Female | 26 |
| Male | 24 |
| Race/Ethnicity, Customized(participants) | Topotecan and Bevacizumab |
|---|---|
| White | 43 |
| African American/African Heritage | 6 |
| White and Mixed Race | 1 |
The record gives a start of Jul 2008, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Topotecan